The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps, MD, PhD, UC San Diego Moores Cancer Center, La Jolla, CA, discusses the genomic assessment of acquired mutations in patients with chronic lymphocytic leukemia (CLL) treated with nemtabrutinib in the Phase II BELLWAVE-003 study (NCT04728893). Dr Kipps notes that analyzing patient samples before, during, and after treatment can provide valuable insights into the dynamics of subclonal evolution and the development of resistance. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
